Inulin-type fructans in psoriasis: body composition, carbohydrate metabolism and energy expenditure — INGUTSKIN RCT
Supplementation with 15 g/day of inulin-type fructans for 8 weeks stabilized fasting glucose in mild psoriasis patients, while the placebo group showed a significant increase.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
Psoriasis patients had higher BMI, visceral fat, and abnormal carbohydrate metabolism parameters compared to healthy controls at baseline. After 8 weeks, the ITF group maintained stable fasting glucose versus an undesirable rise in the placebo group (Δglucose = +5.7 mg/dL; p < 0.01). Energy expenditure findings were not fully disclosed in the available abstract.
How it was done
Double-blind, placebo-controlled RCT; 56 mild psoriasis patients randomized to chicory-derived ITF (15 g/day, n=29) or placebo (n=27) for 8 weeks, with a healthy reference group (n=32).
Risk of bias
The abstract is truncated, precluding assessment of energy expenditure and body composition outcomes. Small sample size and short duration (8 weeks) limit conclusions about sustained effects or clinical relevance of the glycemic difference.
What this study does NOT prove
It cannot be concluded that ITFs improve clinical psoriasis outcomes, reduce systemic inflammation, or produce clinically meaningful changes in body composition based solely on this abstract.
In clinical practice
The glycemic stabilization finding has moderate clinical interest, but the small magnitude (5.7 mg/dL) and incomplete data prevent immediate practical recommendation. Full publication is required.
Limitations
The abstract is truncated, precluding assessment of energy expenditure and body composition outcomes. Small sample size and short duration (8 weeks) limit conclusions about sustained effects or clinical relevance of the glycemic difference.
Technical appendix
Version history
- 1.0 · 2026-07-11 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.